1 Recommendations

1 Recommendations

1.1 Obeticholic acid is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme.

1.2 Assess the response to obeticholic acid after 12 months. Only continue if there is evidence of clinical benefit.

  • National Institute for Health and Care Excellence (NICE)